Literature DB >> 11472353

Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia.

M Sinisalo1, J Aittoniemi, P Oivanen, H Käyhty, R M Olander, J Vilpo.   

Abstract

We investigated responses to vaccination against pneumococcal polysaccharide, Haemophilus influenzae b (Hib) conjugate and tetanus toxoid antigens in 31 patients with chronic lymphocytic leukaemia (CLL) and 25 controls. While in the control group all antibody responses against different antigens were highly significant, in the patient group clear evidence for responsiveness was detected only in the case of Hib polysaccharide antigen. Certain CLL patient subgroups showed low reactivity against tetanus toxoid antigen. In conclusion, plain polysaccharide vaccines seem to be ineffective in patients with CLL. Conjugate vaccines, in turn, are immunogenic and may offer protection against infections caused by encapsulated bacteria in these patients. Further studies concerning an optimal vaccination scheme and clinical efficiency are warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472353     DOI: 10.1046/j.1365-2141.2001.02882.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  26 in total

1.  Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL).

Authors:  Francesca Romana Mauro; Diana Giannarelli; Clementina Maria Galluzzo; Candida Vitale; Andrea Visentin; Costantino Riemma; Serena Rosati; Marika Porrazzo; Sara Pepe; Marta Coscia; Livio Trentin; Massimo Gentile; Sara Raponi; Alessandra Micozzi; Giuseppe Gentile; Silvia Baroncelli
Journal:  Leukemia       Date:  2020-06-17       Impact factor: 11.528

Review 2.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

3.  Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity.

Authors:  Amar Safdar; Gilhen H Rodriguez; Adriana M Rueda; William G Wierda; Alessandra Ferrajoli; Daniel M Musher; Susan O'Brien; Charles A Koller; Gerald P Bodey; Michael J Keating
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

4.  Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia.

Authors:  Vesa Lindström; Janne Aittoniemi; Urpu Salmenniemi; Helena Käyhty; Heini Huhtala; Maija Itälä-Remes; Marjatta Sinisalo
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

Review 5.  How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.

Authors:  Joshua A Hill; Susan K Seo
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

6.  Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia.

Authors:  Vesa Lindström; Janne Aittoniemi; Urpu Salmenniemi; Helena Käyhty; Heini Huhtala; Marjatta Sinisalo
Journal:  Hum Vaccin Immunother       Date:  2019-07-09       Impact factor: 3.452

Review 7.  Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?

Authors:  Fatima Dhalla; Mary Lucas; Anna Schuh; Malini Bhole; Rashmi Jain; Smita Y Patel; Siraj Misbah; Helen Chapel
Journal:  J Clin Immunol       Date:  2014-02-21       Impact factor: 8.317

8.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

9.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.

Authors:  Tetsuya Fukuda; Liguang Chen; Tomoyuki Endo; Li Tang; Desheng Lu; Januario E Castro; George F Widhopf; Laura Z Rassenti; Mark J Cantwell; Charles E Prussak; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

Review 10.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.